Dr Reddy’s told the Delhi High Court it will rename its semaglutide drug from ‘Olymviq’ to ‘Olymra’ after the court raised concerns over similarity with ‘Ozempic’. The case comes as India opens its market to generic semaglutide, leading to rising trademark disputes among drugmakers.
The Delhi High Court directed Dr Reddy’s Laboratories to stop selling or expanding its diabetes drug “Olymviq,” citing phonetic similarity with Novo Nordisk’s “Ozempic.” Justice Jyoti Singh noted such similarity in pharma crosses an unacceptable threshold, indicating prima facie trademark infringement.
The Delhi High Court has expressed concern over the misuse of diabetes drugs like Ozempic for weight loss, directing the Central Drugs Standard Control Organisation to respond in three months. The petition highlights dangerous promotions and potential health risks associated with these medications being used without medical supervision.